News for Exelixis, Inc. (EX9.DE)

PR NewswireVANCOUVER, BC, March 8, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 8, 2025 /PRNewswire/

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. ( OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for

Exelixis Inc (EXEL), a leading oncology company, has announced its participation in several significant investor conferences in March. The company will engage i

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Exelixis, Inc.

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.

Exelixis Inc (EXEL) has announced that its Board of Directors has approved an additional $500 million stock repurchase program, set to be completed by December

Exelixis Inc (EXEL), a prominent biopharmaceutical company known for its cancer treatments, experienced a notable 5.02% increase in its stock price. This positi

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

Revenue: $567 million for Q4 2024, surpassing the estimated $563.42 million.Earnings Per Share (EPS): GAAP diluted EPS of $0.48 for Q4 2024, exceeding the esti

On December 31, 2024, Caligan Partners LP (Trades, Portfolio) made a strategic move by acquiring 15,856,653 shares of Verrica Pharmaceuticals Inc. This transact

Total Revenue: Approximately $567 million for Q4 2024.Cabozantinib Franchise Net Product Revenue: $515.2 million for Q4 2024.CABOMETYX Net Product Revenue: $51

Exelixis, Inc. (NASDAQ:EXEL) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ETCompany ParticipantsSusan Hubbard - Executive Vice President,...

The following slide deck was published by Exelixis, Inc.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Exelixis Inc (EXEL) has released results from a subgroup analysis of the phase 3 CABINET pivotal study, focusing on patients with extra-pancreatic neuroendocrin

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

Exelixis: Truist raises price target citing increased sales potential

Exelixis Inc (EXEL) has released its preliminary unaudited financial results for the fiscal year 2024 and provided financial guidance for 2025. The company anti